Abstract: TH-PO0489
Efficacy of Nefecon and Alteration of Plasma Gd-IgA1 and Poly-IgA Complexes in IgAN in China: Real-World Clinical Practice
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - IgAN
October 22, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Cheng, Wenrong, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China
- Wang, Guoqin, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China
- Li, Jingyi, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China
- Chen, Feifei, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China
- Cheng, Hong, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China
Background
The therapeutic effects of targeted-release formulation of Budesonide(Nefecon) in the NefIgArd trial revealed that Nefecon therapy significantly reduced proteinuria and maintained stable renal function in patients with Immunoglobulin A Nephropathy (IgAN). However, evidence in real-world clinical practice remains limited. To date, no effective biomarkers can predict response to Nefecon in IgAN. The assosiation of plasma galactose-deficient IgA1 (Gd-IgA1) or poly-IgA after Nefecon therapy and proteinuria alteration need to be explored.
Methods
Patients with primary IgAN (proteinuria ≥0.5g/24 hours) received Nefecon and followed at least 3 months were enrolled. The study mainly focused on evaluating alterations in proteinuria and estimated glomerular filtration rate (eGFR), and analysing the levels of plasma Gd-IgA1 and Poly-IgA Complexes during the treatment routine visits.
Results
Forty-two patients were enrolled. The median 24-hour proteinuria was 1.6g (IQR,1.1- 2.9), and median urinary red blood cell count was 85.8(IQR,23.8-232.7)/ul, and the mean baseline eGFR was 66.4ml/min/1.73 m2 (SD=31.9). Proteinuria decreased significantly after 3, 6 and 9 months of Nefecon treatment (median reduction 44.9%, 53.3%and 62.9%, respectively; all p<0.001), while eGFR remained stable. The urinary red blood cells count decreased significantly (all p<0.05). An obvious decrease of Plasma Poly-IgA was observed at 6 months after Nefecon initiation( Mean±SD，133.6±48.5 VS 85.6±29.9 ng/ml, P=0.004)，while plasma Gd-IgA1 did not show the similar trend.
Conclusion
These explores extend trial results to real-world, Nefecon can effectively reduce proteinuria and microscopic hematuria，preserve renal function in IgAN from China. The alternation in plasma poly-IgA Complexes is accompanied by proteinuria reduction.